June 27, 2008 Journal article Open Access

Trumbo PhD, Paula R.; Ellwood, Kathleen C.

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://zenodo.org/record/1230786</identifier>
  <creators>
    <creator>
      <creatorName>Trumbo PhD, Paula R.</creatorName>
      <givenName>Paula R.</givenName>
      <familyName>Trumbo PhD</familyName>
    </creator>
    <creator>
      <creatorName>Ellwood, Kathleen C.</creatorName>
      <givenName>Kathleen C.</givenName>
      <familyName>Ellwood</familyName>
    </creator>
  </creators>
  <titles>
    <title>Chromium Picolinate Intake and Risk of Type 2 Diabetes: An Evidence‐Based Review by the United States Food and Drug Administration</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2008</publicationYear>
  <dates>
    <date dateType="Issued">2008-06-27</date>
  </dates>
  <resourceType resourceTypeGeneral="JournalArticle"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/1230786</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1111/j.1753-4887.2006.tb00220.x</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/publicdomain/zero/1.0/legalcode">Creative Commons Zero v1.0 Universal</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium picolinate intake and insulin resistance is highly uncertain.</description>
  </descriptions>
</resource>